References

Axial spondyloarthritis

10.1016/s0140-6736(24)02263-3 · 2025 · External reference

Gender differences in axial spondyloarthritis: women are not so lucky

10.1007/s11926-018-0744-2 · 2018 · External reference

Does gender influence outcome measures similarly in patients with spondyloarthritis? Results from the ASAS-perSpA study

10.1136/rmdopen-2022-002514 · 2022 · External reference

Female sex, age, and unfavorable response to tumor necrosis factor inhibitors in patients with axial spondyloarthritis: results of statistical and artificial intelligence-based data analyses of a national multicenter prospective registry

10.1002/acr.25048 · 2023 · External reference

Disease activity in women with ankylosing spondylitis remains higher under Tumour Necrosis Factor inhibitor treatment than in men: a five-year observational study

10.1080/03009742.2021.1967046 · 2022 · External reference

Baseline characteristics and treatment response to ixekizumab categorised by sex in radiographic and non-radiographic axial spondylarthritis through 52 weeks: data from three phase III randomised controlled trials

10.1007/s12325-022-02132-2 · 2022 · External reference

Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study

2016 · External reference

Sex-specific diagnostic efficacy of MRI in axial spondyloarthritis: challenging the ‘One Size Fits All’ notion

10.1136/rmdopen-2023-003252 · 2023 · External reference

Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data

10.1093/rheumatology/kez090 · 2019 · External reference

The international map of axial spondyloarthritis survey: a US patient perspective on diagnosis and burden of disease

10.1002/acr2.11543 · 2023 · External reference

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

10.1136/ard-2022-223296 · 2023 · External reference

A pooled analysis reporting the efficacy and safety of secukinumab in male and female patients with ankylosing spondylitis

10.1007/s40744-021-00380-2 · 2021 · External reference

Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis: results from the EuroSpA research collaboration network

10.1136/rmdopen-2023-003325 · 2023 · External reference

Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network

10.1038/s41598-024-52016-4 · 2024 · External reference

Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice

10.1111/1756-185x.13271 · 2018 · External reference

Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies

10.1136/ard-2023-224803 · 2024 · External reference

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials

10.1136/ard-2022-223595 · 2023 · External reference

10.3899/jrheum.2026-0113 · 2026 · Admitted local publication

Bimekizumab was efficacious regardless of age, BMI, CRP, or HLA-B27 status: 1-year results from two phase 3 studies (Abstract 1451)

2025 · External reference

Unresolved reference

External reference

Impact of symptom duration on the short- and long-term efficacy of bimekizumab in axial spondyloarthritis: results up to 2 years

10.1186/s13075-026-03729-6 · 2026 · External reference

P167 Bimekizumab achieved sustained improvements in efficacy outcomes in patients with axial spondyloarthritis, regardless of prior tumour necrosis factor inhibitor treatment: week 52 pooled results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2

2024 · External reference

Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies

10.1093/rheumatology/keaf009 · 2025 · External reference

Heterogeneity of axial spondyloarthritis: genetics, sex and structural damage matter

10.1136/rmdopen-2022-002302 · 2022 · External reference

Achieving inactive disease state in men and women with axial spondyloarthritis: results from a multi-country prospective observational study

10.1093/rheumatology/keaf447 · 2025 · External reference

Sex differences in patient-reported outcome measures and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitors

10.1093/rheumatology/keae370 · 2025 · External reference

Innate immunity at the core of sex differences in osteoarthritic pain?

10.3389/fphar.2022.881500 · 2022 · External reference

Innate immunity and sex: distinct inflammatory profiles associated with murine pain in acute synovitis

10.3390/cells12141913 · 2023 · External reference

Understanding differences between men and women with axial spondyloarthritis

10.1016/j.semarthrit.2020.05.005 · 2020 · External reference

Chronic pain and assessment of pain sensitivity in patients with axial spondyloarthritis: results from the SPARTAKUS cohort

10.3899/jrheum.200872 · 2021 · External reference